Table 2.
The relativity between ACE2 expression and clinicopathological characteristics in NSCLC patients.
| Factors | ACE2 low expression patients(n = 40, %) | ACE2 high expression patients(n = 43, %) | P value | |
|---|---|---|---|---|
| Sex | Male | 15 (37.5) | 27 (62.8) | 0.021 |
| Female | 25 (62.5) | 16 (37.2) | ||
| Age (years) | <65 | 25 (62.5) | 26 (60.5) | 0.849 |
| ≥65 | 15 (37.5) | 17 (39.5) | ||
| Smoking | No | 10 (25.0) | 20 (46.5) | 0.042 |
| Yes | 30 (75.0) | 23 (53.5) | ||
|
Primary tumor
size (diameter) |
≤3 | 25 (62.5) | 25 (58.1) | 0.685 |
| >3 | 15 (37.5) | 18 (41.9) | ||
| Clinical stage | I | 20 (50.0) | 20 (46.5) | 0.936 |
| II | 4 (10.0) | 5 (11.6) | ||
| III | 16 (40.0) | 18 (41.9) | ||
|
Lymph node
status |
N0 | 21 (52.5) | 24 (55.8) | 0.696 |
| N1 | 3 (7.5) | 5 (11.6) | ||
| N2 | 16 (40.0) | 14 (32.6) | ||
| CEA | Negative | 22 (57.9) | 27 (64.3) | 0.558 |
| Positive | 16 (42.1) | 15 (35.7) | ||
| CYFRA21-1 | Negative | 26 (66.7) | 30 (73.2) | 0.526 |
| Positive | 13 (33.3) | 11 (26.8) | ||
| NSE | Negative | 31 (79.5) | 37 (86.0) | 0.430 |
| Positive | 8 (20.5) | 6 (14.0) | ||
| 5-year prognosis | Survival | 19 (47.5) | 30 (71.4) | 0.027 |
| Death | 21 (52.5) | 12 (28.6) | ||
|
5-year recurrence or
metastasis |
Negative | 10 (25.0) | 20 (46.5) | 0.042 |
| Positive | 30 (75.0) | 23 (53.5) | ||
| MV | 39.38 ± 39.33 | 23.03 ± 27.43 | 0.032 | |
| VM | Negative | 32 (80.0) | 24 (55.8) | 0.019 |
| Positive | 8 (20.0) | 19 (44.2) | ||
| VE-cadherin | Negative | 28 (70.0) | 20 (46.5) | 0.030 |
| Positive | 12 (30.0) | 23 (53.5) | ||
| EphA2 | Low expression | 20 (50.0) | 12 (27.9) | 0.039 |
| High expression | 20 (50.0) | 31 (72.1) | ||